AbbVie stock, live, through the tokenised share

Signals, right now

A company built to survive losing its own biggest product

AbbVie spent years preparing for the loss of exclusivity on the drug that once provided most of its profit, by acquiring and developing the products meant to replace it. Whether that succeeded is the entire investment case, and it is answered slowly, in quarterly prescription trends rather than in single events. The seven-day chart is too short a window to say anything about it.

Immunology is a crowded field with switching costs

Patients stable on a biologic are rarely moved without reason, so market share in this category changes slowly even when a better product exists. That inertia cuts both ways and makes revenue unusually forecastable for pharmaceuticals, which is part of why the realised volatility above is typically low between reports.

The dividend is most of the argument, and this token pays none of it

This is held overwhelmingly for income. A backed token generally does not pass dividends through unless the issuer's terms say so, which removes the main reason people own the share in the first place. Use this page to see the price move; do not use the token as a substitute for the holding without reading those terms.

The part we cannot verify

We read the token's price, its traded volume and the value of tokens in issue. We do not audit the custody behind it. The price was checked against the exchange's last close when this page was built and agreed to within about one percent. For the official price, use the exchange or a broker.